---
title: "Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds Higher"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293668725.md"
description: "The stock of Hims surged on Thursday following an FDA panel's suggestion to compound a well-liked peptide for injury recovery. This recommendation led to a significant increase in Hims' stock price. This development made Hims a surprise winner in the FDA showdown regarding peptides."
datetime: "2026-07-23T20:49:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293668725.md)
  - [en](https://longbridge.com/en/news/293668725.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293668725.md)
generator: "portal-rs"
---

# Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds Higher

The stock of Hims surged on Thursday following an FDA panel's suggestion to compound a well-liked peptide for injury recovery. This recommendation led to a significant increase in Hims' stock price. This development made Hims a surprise winner in the FDA showdown regarding peptides.

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md)
- [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md)

## Related News & Research

- [Companies with huge datasets can save up to 80% in AI costs by using open-weight models: Hims CEO](https://longbridge.com/en/news/296307633.md)
- [HIMS stock has quadrupled in 5 years: How Hims turned a $3 stock into a telehealth giant](https://longbridge.com/en/news/296173657.md)
- [Hims & Hers Health (HIMS) Adds AI Weight Loss Care And Smart Scale](https://longbridge.com/en/news/296349696.md)
- [Hims & Hers Chief Legal Officer Soleil Boughton disposes of USD 691,808 in common shares](https://longbridge.com/en/news/296533249.md)
- [Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access](https://longbridge.com/en/news/296381732.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**